Washed Microbiota Transplantation for Allergic Rhinitis
ConditionRhinitis, Allergic
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThe Second Hospital of Nanjing Medical University
About this trial
Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.
Eligibility criteria
Qualifiers
Age 18-65 years old.
Meets the diagnostic criteria for allergic rhinitis.
rTNSS score greater than or equal to 6 points.
The subject or his/her legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.
Disqualifiers
Patients with acute nasosinusitis or upper respiratory tract infection.
Patients diagnosed with chronic sinusitis, nasal septum deviation, nasal polyps, nasal tumors, and other nasal diseases or have undergone nasal surgery.
Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the past two weeks.
Patients with poor lung function.
Trial design
Treatments tested in this trial
- Washed Microbiota Transplantation
- Placebo
Treatment groups
32 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov